Literature DB >> 35258992

Reply to T. Olivier et al.

Jedd D Wolchok1, Harriet Kluger1, Federico Campigotto1, James Larkin1, F Stephen Hodi1.   

Abstract

Entities:  

Year:  2022        PMID： 35258992      PMCID： PMC9084429          DOI： 10.1200/JCO.22.00209

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  7 in total

1.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

2.  Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial.

Authors:  Timothée Olivier; Vinay Prasad
Journal:  J Clin Oncol       Date:  2022-03-08       Impact factor: 50.717

3.  CheckMate-067: Raising the Bar for the Next Decade in Oncology.

Authors:  Sarah A Weiss; Harriet Kluger
Journal:  J Clin Oncol       Date:  2021-12-02       Impact factor: 50.717

4.  Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.

Authors:  Jedd D Wolchok; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier Francesco Ferrucci; Michael Smylie; Marcus O Butler; Andrew Hill; Ivan Márquez-Rodas; John B A G Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Tuba Bas; Corey Ritchings; James Larkin; F Stephen Hodi
Journal:  J Clin Oncol       Date:  2021-11-24       Impact factor: 50.717

5.  Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

Authors:  Frank Stephen Hodi; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Charles Lance Cowey; Christopher D Lao; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier Francesco Ferrucci; Michael Smylie; Andrew Hill; David Hogg; Ivan Marquez-Rodas; Joel Jiang; Jasmine Rizzo; James Larkin; Jedd D Wolchok
Journal:  Lancet Oncol       Date:  2018-10-22       Impact factor: 41.316

6.  Health-related quality of life results from the phase III CheckMate 067 study.

Authors:  Dirk Schadendorf; James Larkin; Jedd Wolchok; F Stephen Hodi; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher Lao; John Wagstaff; Margaret K Callahan; Michael A Postow; Michael Smylie; Pier Francesco Ferrucci; Reinhard Dummer; Andrew Hill; Fiona Taylor; Javier Sabater; Dana Walker; Srividya Kotapati; Amy Abernethy; Georgina V Long
Journal:  Eur J Cancer       Date:  2017-06-23       Impact factor: 9.162

7.  Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067.

Authors:  Meredith M Regan; Charlene M Mantia; Lillian Werner; Ahmad A Tarhini; James Larkin; F Stephen Hodi; Jedd Wolchok; Michael A Postow; Brian Stwalley; Andriy Moshyk; Corey Ritchings; Sandra Re; Wim van Dijck; David F McDermott; Michael B Atkins
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 13.751
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.